- Home
- ADCT
ADCT
ADC Therapeutics SA
as 04-18-2025 1:30pm EST
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.
| Founded: | 2011 | Country: | Switzerland |
| Employees: | N/A | City: | EPALINGES |
| Market Cap: | 131.8M | IPO Year: | 2020 |
| Target Price: | $7.75 | AVG Volume (30 days): | 373.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.05 - $5.17 | Next Earning Date: | 05-05-2025 |
| Revenue: | $70,837,000 | Revenue Growth: | 1.84% |
| Revenue Growth (this year): | 6.82% | Revenue Growth (next year): | 18.56% |
Latest ADC Therapeutics SA News
ADCT Breaking Stock News: Dive into ADCT Ticker-Specific Updates for Smart Investing
PR Newswire
18 days ago
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
PR Newswire
18 days ago
ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
GuruFocus.com
19 days ago
ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Highlights: Navigating Challenges and ...
Simply Wall St.
22 days ago
ADC Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
Zacks
23 days ago
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates
PR Newswire
23 days ago
ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update
PR Newswire
25 days ago
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025
PR Newswire
a month ago
ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025
Compare ADCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADCT ADC Therapeutics SA - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.